2022
DOI: 10.1097/der.0000000000000892
|View full text |Cite
|
Sign up to set email alerts
|

A Case of Facial Contact Dermatitis Due to E-Cigarette Flavored Liquids

Abstract: Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 8 publications
0
0
0
Order By: Relevance